C4X Discovery Holdings plc's (LON:C4XD) half-year results charted a period of significant change which now sees it primed for progress.
It has shifted to developing a high-value, pre-clinical portfolio from which it hopes to create revenue-generating licensing deals. The existing fee-for-service agreements have stopped.
It has a new ‘risk sharing alliance’ with Germany’s Evotec where the pair will work together on a range of small-molecule targets.
CLICK HERE: For a daily round-up of all the Proactive news
At the same time its portfolio has grown from three programmes in addiction, diabetes and chronic obstructive pulmonary disorder in 2014, to eight.
C4X has also made two senior hires - Brad Hoy, who came in as chief financial officer, and Dr Craig Fox, who was appointed chief scientific officer.
Key to executing the new strategy was the successful completion of a £7mln fundraise in March. The proceeds will be used to “continue successful execution of the company's strategy and strengthen the balance sheet as partnering discussions progress”.
"The recent period has seen C4XD make significant progress towards our goal of becoming the world's most productive, self-sustaining drug discovery engine,” said chief executive, Dr Clive Dix.
As is common for the companies at this formative stage of their development, C4X was loss-making. The net loss was £3mln for the six months to January 31.